Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingDevoted Health MRD Testing Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentDevoted HealthPolicy UMGT.CL.0027

    Minimal Residual Disease Testing for Cancer

    Customize your policy alerts

    Sign up for devoted_health Policy UMGT.CL.0027 alerts

    Get alerted when Policy UMGT.CL.0027 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and coverage of minimally invasive molecular DNA and RNA tests used to detect minimal residual disease in patients with a personal history of solid tumors or hematologic malignancies. It applies to all Devoted Health plans and requires testing to align with applicable clinical guidelines and CMS coverage requirements.

    Policy Summary
    PayerDevoted Health
    PolicyMinimal Residual Disease Testing for Cancer
    Policy CodePolicy UMGT.CL.0027
    Change TypeMaterial revision
    Effective DateMarch 11, 2024
    Last ReviewAug 10, 2026
    Next Review DateApril 15, 2027
    Key ActionEnsure the medical record clearly documents MRD test medical necessity, the applicable condition, testing component, and timepoint under the related LCD.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage added for Merkel cell carcinoma and one-time post-surgery MRD testing for stage 2 or 3 colon cancer.

    Coverage for chronic myeloid leukemia and leptomeningeal cancer was removed.

    Coverage added for qualifying muscle-invasive bladder cancer after cystectomy.

    Muscle-invasive bladder cancer criteria were updated during the August 2026 ad hoc review.

    Testing frequency and reimbursement were clarified to follow applicable CMS Billing and Coding Articles and related LCD criteria.

    4Hematologic malignancy groups with specified coverage

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3Specified solid-tumor indications or settings with coverage
    1Post-surgery MRD test for stage 2 or 3 colon cancer
    1 yearPost-cystectomy bladder-cancer testing period
    Every 3 monthsCML BCR-ABL1 monitoring frequency
    NCCNClinical guideline basis

    General Coverage Criteria

    General guideline-supported coverage

    Covered when testing is recommended within applicable NCCN Clinical Practice Guidelines.

    Guideline-supported MRD testing

    • The patient's condition and use of minimal residual disease testing are recommended within applicable National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.

      NCCN guidance establishes the general medical-necessity standard.

    Hematologic malignancies

    MRD testing is medically necessary for the following hematologic conditions.

    Covered hematologic conditions

    • Diagnosis of acute lymphoblastic leukemia (ALL).
    • Diagnosis of acute myeloid leukemia (AML).
    • Diagnosis of multiple myeloma (MM).
    • Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

    Solid tumors

    MRD testing is medically necessary for specified solid-tumor indications.

    Covered solid-tumor indications

    • Diagnosis of Merkel cell carcinoma (MCC).
    • Stage 2 or 3 colon cancer, with testing performed once following surgery.Once following surgery

      MRD testing for metastatic colon cancer is not covered.

    • Muscle-invasive bladder cancer treated without neoadjuvant cisplatin, with pT3, pT4a, or pN+ disease; MRD testing is performed during the one-year post-cystectomy period and may be used to identify patients for whom atezolizumab is recommended.pT3, pT4a, or pN+; during the one-year post-cystectomy period
    • Muscle-invasive bladder cancer treated with neoadjuvant cisplatin, with ypT2 through ypT4a or ypN+ disease; MRD testing is performed during the one-year post-cystectomy period and may be used to identify patients for whom atezolizumab is recommended.

    Chronic myeloid leukemia treatment-response monitoring

    A separate treatment-response testing pathway applies to chronic myeloid leukemia.

    BCR-ABL1 monitoring for CML

    • The member has chronic myeloid leukemia (CML).
    • BCR-ABL1 testing is performed to monitor treatment response.Every three months

    MRD testing for metastatic colon cancer is not covered. Coverage for colon cancer is limited to one MRD test following surgery for stage 2 or 3 disease.

    Testing for conditions not recommended or endorsed within applicable professional clinical guidelines, such as NCCN, is considered investigational and unproven and is not covered.

    Testing performed outside applicable professional clinical guideline recommendations is considered not medically necessary because it is investigational and unproven.

    Covered Cancer Indications

    Specified hematologic malignancies

    MRD testing is medically necessary for the following specified hematologic malignancies, subject to applicable medical-necessity and LCD documentation requirements.

    Specified hematologic malignancy

    • Diagnosis of acute lymphoblastic leukemia (ALL).
    • Diagnosis of acute myeloid leukemia (AML).
    • Diagnosis of multiple myeloma (MM).
    • Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

    Merkel cell carcinoma

    Covered when the medical-necessity requirements and applicable CMS Local Coverage Determination (LCD) criteria are met.

    Eligibility Requirements

    For stage 2 or 3 colon cancer, MRD testing must be performed following surgery and is covered once. Testing for metastatic colon cancer is not covered.

    For qualifying muscle-invasive bladder cancer, MRD testing must be performed after cystectomy and during the one-year post-cystectomy period.

    Non-Covered Services

    MRD testing for metastatic colon cancer is not covered. Coverage for colon cancer applies to one-time testing following surgery for stage 2 or 3 disease.

    MRD testing for conditions not recommended or endorsed by applicable professional clinical guidelines, such as NCCN, is considered investigational and unproven and is not covered.

    Coding and Testing Frequency

    Applicable CMS Local Coverage Determination identifiersmixed
    L38822CGS Administrators, LLC
    L38816Noridian Healthcare Solutions, LLC
    L38814Noridian Healthcare Solutions, LLC
    L38779Palmetto GBA
    L38835WPS Insurance Corporation
    Colon cancer post-surgery testing
    Testing frequencyOnce following surgery for stage 2 or 3 colon cancer
    Chronic myeloid leukemia BCR-ABL1 monitoring
    Monitoring frequencyEvery three months
    Muscle-invasive bladder cancer MRD testing
    Testing periodDuring the one-year post-cystectomy period

    Documentation and Denial Risks

    Documentation Required

    Document medical necessity and testing details

    The medical record must clearly document the medical necessity of the MRD test and support the applicable condition, testing component, and timepoint under the related LCD.

    Documentation Required

    Document bladder cancer treatment details

    For muscle-invasive bladder cancer, document the cystectomy treatment context, relevant pathologic stage, neoadjuvant cisplatin status, and use of MRD testing during the one-year post-cystectomy period to identify potential atezolizumab eligibility.

    Denial Risk

    Confirm guideline support

    Minimal Residual Disease Testing

    Minimal residual disease testing uses highly sensitive, minimally invasive molecular DNA and RNA methods to detect cancer cells that remain in the body after cancer treatment. MRD assessment may help guide treatment, evaluate treatment response, detect recurrence, or provide prognostic information.

    Policy Terms and Acronyms

    Definition
    ctDNACirculating tumor DNA
    Definition
    CMSCenters for Medicare and Medicaid Services
    Definition
    LCDLocal Coverage Determinations
    Definition
    NCCNNational Comprehensive Cancer Network
    Policy Summary
    PayerDevoted Health
    PolicyMinimal Residual Disease Testing for Cancer
    Policy CodePolicy UMGT.CL.0027
    Change TypeMaterial revision
    Effective DateMarch 11, 2024
    Last ReviewAug 10, 2026
    Next Review DateApril 15, 2027
    Key ActionEnsure the medical record clearly documents MRD test medical necessity, the applicable condition, testing component, and timepoint under the related LCD.
    SourceLink
    On This Page
    General Coverage CriteriaCovered Cancer IndicationsEligibility RequirementsNon-Covered ServicesCoding and Testing FrequencyDocumentation and Denial RisksMinimal Residual Disease TestingPolicy Terms and Acronyms
    ypT2–ypT4a or ypN+; during the one-year post-cystectomy period

    Merkel cell carcinoma MRD testing

    • Diagnosis of Merkel cell carcinoma (MCC).
    • The MRD test meets applicable medical-necessity requirements and the criteria in the applicable CMS LCD.

    One-time post-surgery MRD testing for stage 2 or 3 colon cancer

    Covered for one-time MRD testing after surgery for stage 2 or 3 colon cancer.

    Post-surgery colon cancer MRD testing

    • The patient has stage 2 or 3 colon cancer.
    • Testing is performed following surgery.
    • The MRD test is performed once.Once following surgery
    • The disease is not metastatic.

      MRD testing for metastatic colon cancer is not covered.

    Qualifying muscle-invasive bladder cancer

    Covered during the one-year post-cystectomy period when the patient meets one of the qualifying muscle-invasive bladder cancer pathways.

    • The patient has muscle-invasive bladder cancer and has undergone cystectomy.
    • Qualifying treatment and pathologic stage

      • The cancer was treated without neoadjuvant cisplatin and has pT3, pT4a, or pN+ disease.
      • The cancer was treated with neoadjuvant cisplatin and has ypT2 through ypT4a or ypN+ disease.
    • MRD testing is performed during the one-year post-cystectomy period.During the one-year post-cystectomy period

      Testing may be used to identify patients for whom atezolizumab is recommended; patients who test positive are eligible for treatment under the stated use case.

    BCR-ABL1 testing for chronic myeloid leukemia treatment-response monitoring

    Covered for treatment-response monitoring in chronic myeloid leukemia.

    BCR-ABL1 treatment-response monitoring

    • The member has chronic myeloid leukemia (CML).
    • Testing is BCR-ABL1 molecular testing to monitor treatment response.
    • Testing is performed every three months.Every three months

    MRD testing may be denied when the condition is not recommended or endorsed by applicable professional clinical guidelines, such as NCCN. Testing for such conditions is considered investigational and unproven and is not covered.

    Denial Risk

    Do not order MRD testing for metastatic colon cancer

    MRD testing for metastatic colon cancer is not covered.

    Denial Risk

    Avoid insufficient medical-necessity documentation

    Testing may be denied when the medical record does not clearly document medical necessity as required by the applicable LCD.

    Denial Risk

    Ensure serial testing is reasonable and necessary

    Individual components or timepoints of a serial MRD testing service may be denied if they are not reasonable and necessary or do not meet the related LCD criteria.

    Definition
    UMUtilization Management